Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company's products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:ELOS
- CUSIP: N/A
- Web: syneron-candela.com
Average Prices:- 50 Day Moving Avg: $10.90
- 200 Day Moving Avg: $10.14
- 52 Week Range: $6.18 - $11.43
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 21.15
- P/E Growth: 0.00
Profitability:- Net Margins: -1.09%
- Return on Equity: -1.74%
- Return on Assets: -1.30%
Debt:- Current Ratio: 2.68%
- Quick Ratio: 1.84%
Misc:- Average Volume: 797,289 shs.
- Beta: 1.25
Frequently Asked Questions for Syneron Medical (NASDAQ:ELOS)
What is Syneron Medical's stock symbol?
Syneron Medical trades on the NASDAQ under the ticker symbol "ELOS."
How were Syneron Medical's earnings last quarter?
Syneron Medical Ltd. (NASDAQ:ELOS) announced its quarterly earnings data on Thursday, August, 4th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.03. The firm earned $75 million during the quarter, compared to analyst estimates of $75.72 million. Syneron Medical had a negative net margin of 1.09% and a negative return on equity of 1.74%. Syneron Medical's revenue was up 2.0% on a year-over-year basis. During the same period last year, the firm posted $0.07 EPS. View Syneron Medical's Earnings History.
Where is Syneron Medical's stock going? Where will Syneron Medical's stock price be in 2017?
2 brokers have issued twelve-month price targets for Syneron Medical's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Syneron Medical's share price to reach $11.00 in the next year. View Analyst Ratings for Syneron Medical.
What are analysts saying about Syneron Medical stock?
Here are some recent quotes from research analysts about Syneron Medical stock:
- 1. Maxim Group analysts commented, "On May 10, 2017, ELOS announced the expiration of the go-shop" period under its merger agreement with Apax Partners. During the go-shop period, ELOS engaged in an active and extensive solicitation of 59 potential bidders, which resulted in two potential bidders each negotiating and entering into a confidentiality agreement. However, they subsequently confirmed that they weren’t interested in pursuing an acquisition of ELOS. The acquisition by Apax Partners is expected to be completed during 3Q17, subject to ELOS shareholder approval and the satisfaction of other customary closing conditions." (5/12/2017)
- 2. According to Zacks Investment Research, "Syneron Medical Ltd. manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented ELOS combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative ELOS technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications. " (1/11/2017)
Who are some of Syneron Medical's key competitors?
Some companies that are related to Syneron Medical include Baxter International (BAX), C.R. Bard (BCR), Zimmer Biomet Holdings (ZBH), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), STERIS PLC (STE), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO) and Haemonetics Corporation (HAE).
Who are Syneron Medical's key executives?
Syneron Medical's management team includes the folowing people:
- Shimon Eckhouse Ph.D., Chairman of the Board
- Amit Meridor, Chief Executive Officer
- Hugo Goldman, Chief Financial Officer
- Erik Dowell, Vice President-North America
- William Griffing, Chief Executive Officer - Syneron Candela North America
- Shlomo Alkalay, Chief Operating Officer
- Lisa A. Soderquist, Chief Human Resource Officer
- Robert Ruck, Executive Vice President, Asia Pacific
- Robert Fielitz, Vice President and Managing Director of Europe, Middle East and Africa
- Sarit Soccary Ben-Yochanan, Vice President - Business Development & Strategy
Who owns Syneron Medical stock?
Syneron Medical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (0.00%),
BRANDES INVESTMENT PARTNERS, LP
(9.87%), CNH Partners LLC (0.00%), K2 Principal Fund L.P. (0.00%), Vivaldi Asset Management LLC (0.00%) and Dalton Greiner Hartman Maher & Co. (2.52%). View Institutional Ownership Trends for Syneron Medical.
Who sold Syneron Medical stock? Who is selling Syneron Medical stock?
Syneron Medical's stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Brandes Investment Partners LP, Lapides Asset Management LLC, Ameriprise Financial Inc., Profit Investment Management LLC, QS Investors LLC, Eagle Global Advisors LLC and California Public Employees Retirement System. View Insider Buying and Selling for Syneron Medical.
Who bought Syneron Medical stock? Who is buying Syneron Medical stock?
Syneron Medical's stock was purchased by a variety of institutional investors in the last quarter, including CNH Partners LLC, K2 Principal Fund L.P., Vivaldi Asset Management LLC, SG Americas Securities LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Mizuho Securities USA LLC, City Financial Investment Co Ltd and Virtu KCG Holdings LLC. View Insider Buying and Selling for Syneron Medical.
How do I buy Syneron Medical stock?
Shares of Syneron Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneron Medical's stock price today?
One share of Syneron Medical stock can currently be purchased for approximately $11.00.
MarketBeat Community Rating for Syneron Medical (NASDAQ ELOS)MarketBeat's community ratings are surveys of what our community members think about Syneron Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Syneron Medical (NASDAQ:ELOS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $11.00 (0.00% downside) |
Analysts' Ratings History for Syneron Medical (NASDAQ:ELOS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/12/2017 | Maxim Group | Downgrade | Buy -> Hold | $12.00 -> $11.00 | Medium |  |
| 10/24/2016 | Brean Capital | Reiterated Rating | Buy | | N/A | |
| 8/5/2016 | Leerink Swann | Downgrade | Outperform -> Market Perform | $9.40 -> $7.80 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Syneron Medical (NASDAQ:ELOS)Earnings History by Quarter for Syneron Medical (NASDAQ ELOS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/15/2017 | Q416 | $0.03 | ($0.03) | $82.02 million | $82.90 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.02) | $0.02 | $68.08 million | $71.50 million | View | Listen | |
| 8/4/2016 | Q216 | $0.06 | $0.09 | $75.72 million | $75.00 million | View | Listen | |
| 5/19/2016 | Q116 | $0.01 | $0.04 | $64.38 million | $68.70 million | View | Listen | |
| 2/22/2016 | Q415 | $0.07 | $0.07 | $75.56 million | $78.90 million | View | Listen | |
| 11/11/2015 | Q315 | $0.03 | $0.03 | $66.60 million | $62.10 million | View | Listen | |
| 8/4/2015 | Q215 | $0.06 | $0.04 | $70.93 million | $73.50 million | View | N/A | |
| 5/13/2015 | Q115 | $0.01 | $0.02 | $62.08 million | $63.40 million | View | Listen | |
| 2/18/2015 | Q414 | $0.06 | $0.09 | $71.42 million | $74.10 million | View | N/A | |
| 11/12/2014 | Q314 | $0.03 | $0.03 | $58.32 million | $60.30 million | View | N/A | |
| 8/6/2014 | Q214 | $0.07 | $0.07 | $63.52 million | $64.60 million | View | Listen | |
| 5/14/2014 | Q114 | $0.04 | $0.04 | $55.50 million | $56.80 million | View | N/A | |
| 2/20/2014 | Q413 | $0.08 | $0.11 | $65.70 million | $64.30 million | View | Listen | |
| 11/13/2013 | Q313 | $0.01 | $0.04 | $62.06 million | $62.70 million | View | Listen | |
| 8/14/2013 | Q2 2013 | $0.09 | $0.02 | $70.93 million | $68.80 million | View | N/A | |
| 5/22/2013 | Q1 2013 | $0.02 | $0.02 | $61.19 million | $61.20 million | View | N/A | |
| 2/12/2013 | Q4 2012 | $0.09 | $0.11 | $70.60 million | $72.80 million | View | N/A | |
| 11/7/2012 | Q312 | $0.04 | $0.03 | $65.51 million | $60.13 million | View | N/A | |
| 8/15/2012 | | $0.04 | $0.05 | | | View | N/A | |
| 2/9/2012 | | $0.04 | $0.03 | | | View | N/A | |
| 11/10/2011 | | ($0.09) | ($0.03) | | | View | N/A | |
| 8/11/2011 | | ($0.02) | ($0.01) | | | View | N/A | |
| 5/19/2011 | | ($0.04) | $0.01 | | | View | N/A | |
| 2/16/2011 | | ($0.04) | $0.24 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Syneron Medical (NASDAQ:ELOS)Current Year EPS Consensus Estimate: $0.33 EPS
Next Year EPS Consensus Estimate: $0.52 EPS
Dividend History for Syneron Medical (NASDAQ:ELOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Syneron Medical (NASDAQ:ELOS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Syneron Medical (NASDAQ:ELOS)
Latest Headlines for Syneron Medical (NASDAQ:ELOS)
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Contrast: Syneron Medical (ELOS) and Its Competitors
www.americanbankingnews.com - September 20 at 2:23 PM |
| Intersect ENT (XENT) versus Syneron Medical (ELOS) Head to Head Comparison
www.americanbankingnews.com - September 19 at 2:30 PM |
| Comparing Syneron Medical (ELOS) & Align Technology (ALGN)
www.americanbankingnews.com - July 27 at 9:10 AM |
 | Syneron Candela Completes Previously Announced Transaction with Funds Advised by Apax Partners and Becomes a Private Company
finance.yahoo.com - July 17 at 11:14 AM |
 | Medtech Mergers Surge Again
seekingalpha.com - July 10 at 11:12 PM |
| ETFs with exposure to Syneron Medical Ltd. : July 10, 2017
finance.yahoo.com - July 10 at 6:07 PM |
| Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : July 7, 2017
finance.yahoo.com - July 8 at 10:29 AM |
| Syneron Medical Ltd. (NASDAQ:ELOS) Downgraded by BidaskClub
www.americanbankingnews.com - July 7 at 12:38 AM |
| Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : June 21, 2017
finance.yahoo.com - June 21 at 6:30 PM |
| ETFs with exposure to Syneron Medical Ltd. : June 19, 2017
finance.yahoo.com - June 19 at 6:36 PM |
| Syneron Medical Ltd. :ELOS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 5:49 PM |
| Syneron Candela Announces Shareholder Approval of Proposed Acquisition by Funds Advised by Apax Partners
finance.yahoo.com - June 15 at 7:00 PM |
| Syneron Medical Ltd. (ELOS) Short Interest Up 6.3% in May
www.americanbankingnews.com - June 11 at 7:28 AM |
| Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : May 29, 2017
finance.yahoo.com - May 29 at 10:58 AM |
| Syneron Medical Ltd. – Value Analysis (NASDAQ:ELOS) : May 18, 2017
finance.yahoo.com - May 18 at 5:28 PM |
| Syneron Medical Reports First Quarter 2017 Revenue of $66.9 Million
finance.yahoo.com - May 17 at 9:59 PM |
| Syneron Medical reports 1Q loss
finance.yahoo.com - May 17 at 9:59 PM |
| Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : May 17, 2017
finance.yahoo.com - May 17 at 10:59 AM |
| Syneron Medical Ltd. (ELOS) Cut to "Hold" at Maxim Group
www.americanbankingnews.com - May 12 at 8:20 AM |
 | Syneron Candela (ELOS) Announces Expiration of Go-Shop Period
www.streetinsider.com - May 10 at 5:06 PM |
| Syneron Candela Announces End of Go-Shop Period
finance.yahoo.com - May 10 at 7:26 AM |
| Syneron Medical (ELOS) Given Media Sentiment Rating of 0.14
www.americanbankingnews.com - May 3 at 1:26 PM |
| Syneron Medical (ELOS) Receives News Sentiment Score of 0.56
www.americanbankingnews.com - April 29 at 9:43 AM |
| Syneron Medical (ELOS) Earns Coverage Optimism Score of 0.14
www.americanbankingnews.com - April 24 at 3:40 PM |
| Syneron Medical (ELOS) Receives News Impact Score of 0.10
www.americanbankingnews.com - April 20 at 5:00 PM |
| Syneron Medical (ELOS) Getting Very Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 15 at 8:26 AM |
 | Apax to buy Israeli aesthetic device firm Syneron for $397 mln
us.rd.yahoo.com - April 3 at 10:17 PM |
| Apax to buy Israeli aesthetic device firm Syneron for $397 million
us.rd.yahoo.com - April 3 at 10:17 PM |
 | Syneron Medical (ELOS) Jumps on Apax Deal
www.baystreet.ca - April 3 at 5:16 PM |
 | Syneron Medical Agrees To Be Bought By Apax Partners For $397 Mln - Quick Facts
www.nasdaq.com - April 3 at 5:16 PM |
 | Syneron Medical Ltd. stock rises after nearly $400 mln acquisition of outstanding shares
www.marketwatch.com - April 3 at 5:16 PM |
| Apax eyes IPO for investment house Psagot in Tel Aviv -source
uk.finance.yahoo.com - April 3 at 7:18 AM |
| Syneron Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for $11.00/share in Cash, Representing an Approximate Value of $397 Million
finance.yahoo.com - April 3 at 7:18 AM |
| Apax close to $500 mln deal to buy Israel's Syneron - reports
uk.finance.yahoo.com - April 2 at 8:31 AM |
| SYNERON MEDICAL LTD. Financials
finance.yahoo.com - March 29 at 5:28 PM |
| Form 6-K Syneron Medical Ltd. For: Mar 27 - StreetInsider.com
www.streetinsider.com - March 28 at 9:40 PM |
| Syneron Candela Announces CE Mark for CO2RE® Intima
finance.yahoo.com - March 27 at 11:59 AM |
| Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website
finance.yahoo.com - March 23 at 5:28 PM |
| Syneron Candela Announces New Technology and Indications at the 2017 American Academy of Dermatology (AAD) Annual Meeting
finance.yahoo.com - March 1 at 4:39 PM |
| Syneron Medical: Still Frustrating - And Still Tantalizing - Seeking Alpha
seekingalpha.com - February 24 at 5:43 PM |
 | Syneron Medical 4Q Loss 3 Cents a Share (ELOS)
www.investopedia.com - February 16 at 4:40 PM |
 | Syneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million
us.rd.yahoo.com - February 16 at 4:40 PM |
| 7:02 am Syneron Medical beats by $0.05, beats on revs
us.rd.yahoo.com - February 16 at 4:40 PM |
| Q4 2016 Syneron Medical Ltd Earnings Release - Before Market Open
us.rd.yahoo.com - February 16 at 4:40 PM |
| Syneron Medical Reports 4Q Loss of 3 Cents a Share
www.investopedia.com - February 16 at 4:40 PM |
| Edited Transcript of ELOS earnings conference call or presentation 15-Feb-17 1:30pm GMT
finance.yahoo.com - February 16 at 7:42 AM |
| UPDATE 2-Hologic buys Cynosure to expand into medical aesthetics - Nasdaq
www.nasdaq.com - February 14 at 5:51 PM |
| Syneron Medical to Participate in Leerink Partners 6th Annual Global Healthcare Conference
finance.yahoo.com - February 13 at 5:42 PM |
| Apax Partners in talks to buy Israel's Syneron Medical -report
finance.yahoo.com - February 13 at 7:43 AM |
| Sientra (SIEN) Names Philippe Schaison to Board of Directors
www.streetinsider.com - February 7 at 6:06 PM |
Syneron Medical (ELOS) Chart for Monday, September, 25, 2017
